Literature DB >> 28254114

Genetic polymorphism in matrix metalloproteinase-9 and transforming growth factor-β1 and susceptibility to combined pulmonary fibrosis and emphysema in a Chinese population.

Ling Xu1, Wei Bian2, Xiao-Hua Gu2, Ce Shen2.   

Abstract

In this study, we aimed to explore the association of genetic polymorphism in matrix metalloproteinase-9 (MMP-9) and transforming growth factor-β1 (TGF-β1) and the susceptibility to combined pulmonary fibrosis and emphysema (CPFE). We examined the polymorphisms of the MMP-9 C-1562T and TGF-β1 T869C in 38 CPFE patients, 50 pulmonary emphysema patients, and 34 idiopathic pulmonary fibrosis (IPF) patients. The frequencies of polymorphic genotypes in MMP-9 were 78.95% CC and 21.05% CT in CPFE group, 76.0% CC and 24.0% CT in emphysema group, and 100.0% CC in IPF group. There were highly statistically significant increased frequencies of the CT genotype and T allele in CPFE and emphysema groups compared with IPF group (p < 0.05). The frequencies of polymorphic genotypes in TGF-β1 were 2.63% CC, 28.95% CT, 68.42% TT in CPFE group, 4.00% CC, 16.00% CT, 80.00% TT in emphysema group, and 5.88% CC, 41.18% CT, 52.94% TT in IPF group. Significant increases in the TT genotype and T allele frequencies were observed in emphysema group compared with IPF group (p < 0.05). Our study has showed that T allele in MMP-9 (C-1562T) and T allele in TGF-β1 (T869C) are risk factors of pulmonary emphysema. The T allele in MMP-9 (C-1562T) possibly predisposes patients with pulmonary fibrosis to develop emphysema.
Copyright © 2017. Published by Elsevier Taiwan.

Entities:  

Keywords:  Emphysema; Genetic polymorphism; Matrix metalloproteinase-9; Pulmonary fibrosis; Transforming growth factor-β1

Mesh:

Substances:

Year:  2017        PMID: 28254114     DOI: 10.1016/j.kjms.2016.12.004

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  7 in total

1.  Increased Serum Levels of Matrix-metalloproteinase-9, Cyclo-oxygenase-2 and Prostaglandin E-2 in Patients with Chronic Obstructive Pulmonary Disease (COPD).

Authors:  Ajay Kumar Verma; Anuj Kumar Pandey; Arpita Singh; Surya Kant; Abbas Ali Mahdi; Ved Prakash; Kausar Mahmood Ansari; Rakesh Kumar Dixit; Shyam Chand Chaudhary
Journal:  Indian J Clin Biochem       Date:  2021-04-17

Review 2.  Matrix Metalloproteinases and Their Inhibitors in Pulmonary Fibrosis: EMMPRIN/CD147 Comes into Play.

Authors:  Lourdes Chuliá-Peris; Cristina Carreres-Rey; Marta Gabasa; Jordi Alcaraz; Julián Carretero; Javier Pereda
Journal:  Int J Mol Sci       Date:  2022-06-21       Impact factor: 6.208

3.  The association between transforming growth factor beta1 polymorphism and susceptibility to pulmonary fibrosis: A meta-analysis (MOOSE compliant).

Authors:  Lili Xin; Miao Jiang; Guangbao Su; Miao Xie; Hui Chen; Xiao Liu; Muge Xu; Geng Zhang; Jiening Gong
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

4.  Relationship Between Circulating Serpina3g, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinase-1 and -2 with Chronic Obstructive Pulmonary Disease Severity.

Authors:  Pelin Uysal; Hafize Uzun
Journal:  Biomolecules       Date:  2019-02-13

5.  Genetic polymorphism of matrix metalloproteinase 9 and susceptibility to chronic obstructive pulmonary disease: A meta-analysis.

Authors:  Xiaoping Yang; Yuanyuan Yu; Yong Wang; Wen Jiang; Wenqing Jiang; Bin Yin
Journal:  J Med Biochem       Date:  2022-07-29       Impact factor: 2.157

6.  Medical Data Analysis of CYP1B1 Gene Polymorphism and Clinical Prognosis of Minimally Invasive Surgery for Lung Cancer.

Authors:  Xia Han; Danqing Li; Shaofeng Zhang
Journal:  Biomed Res Int       Date:  2022-09-24       Impact factor: 3.246

7.  Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis.

Authors:  Milena S Espindola; David M Habiel; Ana Lucia Coelho; Barry Stripp; William C Parks; Justin Oldham; Fernando J Martinez; Imre Noth; David Lopez; Amanda Mikels-Vigdal; Victoria Smith; Cory M Hogaboam
Journal:  Am J Respir Crit Care Med       Date:  2021-02-15       Impact factor: 21.405

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.